IPHA Innate Pharma S.A. Stock Quote

IPHA [NASD]

Index	-	P/E	-	EPS (ttm)	-	Insider Own	1.55%	Shs Outstand	79.01M	Perf Week	-12.05%
Market Cap	559.38M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	51.13M	Perf Month	109.29%
Income	-	PEG	-	EPS next Q	-	Inst Own	0.38%	Short Float	0.15%	Perf Quarter	105.22%
Sales	70.45M	P/S	7.94	EPS this Y	-	Inst Trans	-	Short Ratio	0.03	Perf Half Y	52.92%
Book/sh	-	P/B	-	EPS next Y	-	ROA	-	Target Price	7.14	Perf Year	68.97%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	3.02 - 11.95	Perf YTD	73.11%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-40.75%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	134.44%	ATR	0.93
Employees	244	Current Ratio	-	Sales Q/Q	26.40%	Oper. Margin	-	RSI (14)	65.18	Volatility	8.00% 19.15%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.10	Prev Close	6.70
Shortable	Yes	LT Debt/Eq	-	Earnings	Sep 15 BMO	Payout	-	Avg Volume	2.33M	Price	7.08
Recom	1.80	SMA20	22.33%	SMA50	64.71%	SMA200	66.36%	Volume	234,892	Change	5.67%

Sep-03-21

Upgrade

SVB Leerink

Mkt Perform → Outperform

Dec-15-20

Downgrade

SVB Leerink

Outperform → Mkt Perform

$7 → $5

Nov-24-20

Initiated

Goldman

Neutral

$4.75

Sep-23-21 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021 GlobeNewswire
Sep-20-21 04:58AM	48 Biggest Movers From Friday Benzinga
Sep-17-21 03:10PM	Mid-Afternoon Market Update: Nasdaq Down 1%; Protagonist Therapeutics Shares Plummet Benzinga +40.87%
01:21PM	Here's Why Innate Pharma Stock Is Rocketing Higher Today Motley Fool
10:10AM	What Is Happening With Innate Pharma Stock On Friday? Benzinga
07:45AM	Monalizumab Data From COAST Trial Presented at ESMO Congress 2021 GlobeNewswire
07:45AM	Monalizumab Data from COAST Trial Presented at ESMO Congress 2021 GlobeNewswire
07:06AM	15 Stocks Moving in Friday's Pre-Market Session Benzinga
Sep-15-21 01:00AM	Innate Pharma reports first half 2021 financial results and business update GlobeNewswire
Sep-09-21 10:39PM	Is Innate Stock Still Worth Buying After Its Recent Rally? Analyst Weighs In TipRanks
Sep-07-21 01:00AM	Innate Pharma Announces Conference Call and Webcast for First Half 2021 Business Update GlobeNewswire -5.20%
Sep-03-21 12:48PM	Why Innate Pharma Shares Are Rising On Friday? Benzinga +47.13%
07:01AM	20 Stocks Moving in Friday's Pre-Market Session Benzinga
Sep-02-21 12:05PM	Mid-Day Market Update: Crude Oil Jumps Over 2%; Assembly Biosciences Shares Plunge Benzinga +15.47%
12:03PM	46 Stocks Moving In Thursday's Mid-Day Session Benzinga
02:00AM	Monalizumab and ANKET Data Will Be Presented at ESMO 2021 Virtual Congress GlobeNewswire
Aug-30-21 01:00AM	Innate Pharma to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-11-21 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of August 1, 2021 GlobeNewswire
Jul-12-21 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of July 1, 2021 GlobeNewswire
Jul-06-21 07:16AM	Innate Pharma To Stop COVID-19 Trial With Avdoralimab After Mid-Stage Study Disappoints Benzinga
01:00AM	Update on Avdoralimab Phase 2 FORCE Trial in COVID-19 Patients with Severe Pneumonia GlobeNewswire
01:00AM	Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients With Severe Pneumonia GlobeNewswire
Jun-22-21 09:32AM	Innate Pharma's Lacutamab Shows Clinical Responses In KIR3DL2-Expressing Mycosis Fungoides Patients Benzinga -5.92%
07:00AM	Innate Pharma Presents Preliminary Data from TELLOMAK Trial Showing Clinical Response for Lacutamab in Mycosis Fungoides GlobeNewswire
07:00AM	Innate Pharma presents preliminary data from TELLOMAK trial showing clinical response for lacutamab in mycosis fungoides GlobeNewswire
Jun-16-21 01:00AM	Innate Pharma to Host Virtual Investor Event to Highlight Progress Against Company Strategy GlobeNewswire
Jun-14-21 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of June 1, 2021 GlobeNewswire
Jun-10-21 01:00AM	Innate Pharma Presents New Data on Next-Generation NK Cell Engager Platform at FOCIS 2021 Annual Meeting GlobeNewswire +7.83%
Jun-09-21 06:00AM	New Lacutamab Data From Tellomak Trial to be Showcased in Oral Presentation at Upcoming 16th International Conference on Malignant Lymphoma GlobeNewswire
06:00AM	New Lacutamab Data from TELLOMAK Trial to be Showcased in Oral Presentation at Upcoming 16th International Conference on Malignant Lymphoma GlobeNewswire
May-28-21 04:01PM	Outcome of Innate Pharmas Annual General Meeting GlobeNewswire
May-25-21 01:00AM	Number of Shares and Voting Rights of Innate Pharma as of May 1, 2021 GlobeNewswire
May-12-21 01:00AM	Innate Pharma Virtual 2021 Annual General Meeting GlobeNewswire
May-11-21 01:00AM	Innate Pharma First Quarter 2021 Report GlobeNewswire +6.22%
May-04-21 01:00AM	Innate Pharma Announces Conference Call and Webcast for 2021 First Quarter Business Update GlobeNewswire
Apr-28-21 01:00AM	Innate Pharma Files Its 2020 Universal Registration Document (Document Denregistrement Universel) and 2020 Annual Report on Form 20-F GlobeNewswire
01:00AM	Innate Pharma Files its 2020 Universal Registration Document (Document d'Enregistrement Universel) and 2020 Annual Report on Form 20-F GlobeNewswire
Apr-21-21 01:00AM	Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 28, 2021 GlobeNewswire
01:00AM	Innate Pharma to Hold its Annual General Meeting of Shareholders on May 28, 2021 GlobeNewswire
Apr-19-21 01:00AM	NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF APRIL 1, 2021 GlobeNewswire
01:00AM	Number of Shares and Voting Rights of Innate Pharma as of April 1, 2021 GlobeNewswire
Mar-18-21 02:00AM	Innate Pharma Reports Full Year 2020 Financial(1) Results and Business Update GlobeNewswire
02:00AM	Innate Pharma reports Full Year 2020 financial results and business update GlobeNewswire
Mar-16-21 02:00AM	Innate Pharma Announces Conference Call and Webcast for Full Year 2020 Financial Results GlobeNewswire
02:00AM	Innate Pharma announces conference call and webcast for Full Year 2020 financial results GlobeNewswire
Feb-24-21 01:00AM	Number of shares and voting rights of Innate Pharma as of February 1, 2021 GlobeNewswire
Feb-17-21 01:00AM	Innate Pharma to Participate in the 10th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
01:00AM	Innate Pharma to participate in the 10th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-09-21 07:30AM	QuestEx Gold & Copper Announces 2020 Exploration Results from their 100% Owned Sofia Property and Delineation of 2021 Drill-Ready Targets CNW Group
07:19AM	Innate Pharma To Test Lacutamab In Relapsed/Refractory Peripheral T-Cell Lymphoma Patients Benzinga
01:00AM	Innate Pharma Advances Lacutamab Clinical Development Program GlobeNewswire
01:00AM	Innate Pharma advances lacutamab clinical development program GlobeNewswire
Feb-03-21 01:00AM	Innate Pharma to Host Key Opinion Leader Discussion on the Potential Role of Lacutamab Across T-Cell Lymphomas GlobeNewswire +6.27%
01:00AM	Innate Pharma to host key opinion leader discussion on the potential role of lacutamab across T-cell lymphomas GlobeNewswire
Jan-05-21 01:00AM	Innates First NK Cell Engager Selected by Sanofi as Drug Candidate for Development GlobeNewswire
01:00AM	Innate's first NK cell engager selected by Sanofi as drug candidate for development GlobeNewswire
Jan-04-21 01:00AM	Innate Pharma to Participate in Upcoming Investor Conferences GlobeNewswire +5.38%
Dec-22-20 12:00PM	FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Innate Pharma S.A. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
10:00AM	IPHA Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Innate Pharma S.A. Investors of Class Action and Lead Plaintiff Deadline: December 22, 2020 Newsfile
09:12AM	INNATE FINAL DEADLINE: ROSEN, A LONSTANDING LAW FIRM, Reminds Innate Pharma S.A. Investors of Important Deadline Today in Securities Class Action Commenced by the Firm IPHA GlobeNewswire
12:35AM	FINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Innate Pharma S.A. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Dec-21-20 07:31PM	Innate Pharma, S.A.: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm GlobeNewswire
07:13PM	DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Innate Pharma S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm PR Newswire
12:54PM	IPHA FINAL DEADLINE NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Reminds Innate Pharma S.A. Investors of Important Tuesday Deadline in Securities Class Action - IPHA Newsfile
12:30PM	FINAL DEADLINE TOMORROW The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Innate Pharma S.A. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
11:30AM	DEADLINE ALERT for LVS, IPHA, JPM, and FAF: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
11:00AM	IPHA Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Innate Pharma S.A. Investors of Class Action and Lead Plaintiff Deadline: December 22, 2020 Business Wire
Dec-20-20 01:10PM	FINAL DEADLINE THIS WEEK: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Innate Pharma S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
01:00PM	LVS, IPHA & JPM Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Shareholders to Contact the Firm ACCESSWIRE
Dec-19-20 02:25PM	IPHA Deadline Alert: Rosen, A Trusted and Top Ranked Law Firm, Reminds Innate Pharma S.A. Investors of Important December 22 Deadline in Securities Class Action - IPHA Newsfile
08:25AM	IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Innate Pharma S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
Dec-18-20 08:00PM	DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Innate Pharma S.A. and Encourages Investors to Contact the Firm Business Wire
07:00PM	IPHA LOSS ALERT: ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Innate Pharma S.A. Investors to Seek Counsel Before Important December 22 Deadline in Securities Class Action IPHA ACCESSWIRE
01:00PM	LVS, IPHA & JPM Looming Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Encourages Shareholders to Contact the Firm ACCESSWIRE
12:15PM	IMPORTANT DECEMBER DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Innate Pharma S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
11:47AM	DEC. 22 DEADLINE: Zhang Investor Law Reminds Innate Pharma S.A. Investors with Losses of December 22 Deadline in Securities Class Action IPHA GlobeNewswire
11:15AM	The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA) Business Wire
Dec-17-20 07:45PM	ROSEN, A LEADING LAW FIRM, Reminds Innate Pharma S.A. Investors of Important December 22 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm IPHA GlobeNewswire
Dec-16-20 02:05PM	FINAL DEADLINE IMMINENT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Innate Pharma S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
12:00PM	LVS, IPHA & JPM Looming Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Encourages Shareholders to Contact the Firm GlobeNewswire
11:00AM	DEADLINE ALERT for LVS, IPHA, JPM, and FAF: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Dec-15-20 06:52PM	ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Reminds Innate Pharma S.A. Investors of Important December 22 Deadline in Securities Class Action - IPHA PR Newswire
11:00AM	DEADLINE ALERT for LVS, IPHA, FBIO, and SPLK: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Dec-14-20 01:00PM	Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA) PR Newswire
12:25PM	IMPORTANT DECEMBER DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Innate Pharma S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
11:00AM	LVS, IPHA & JPM Upcoming Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Encourages Shareholders to Contact the Firm ACCESSWIRE
Dec-12-20 10:31PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innate Pharma S.A. - IPHA GlobeNewswire
Dec-11-20 03:10PM	SHAREHOLDER DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Innate Pharma S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE -18.66%
12:20PM	Zhang Investor Law Reminds Innate Pharma S.A. Investors with Losses of December 22 Deadline in Securities Class Action IPHA GlobeNewswire
01:00AM	Innate Pharma to return US and EU Lumoxiti commercialization rights to AstraZeneca GlobeNewswire
Dec-10-20 01:15PM	FINAL DEADLINE RAPIDLY APPROACHING: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Innate Pharma S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
Dec-09-20 10:45PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innate Pharma S.A. - IPHA ACCESSWIRE -5.19%
04:25PM	Rosen, Trusted National Trial Counsel, Reminds Innate Pharma S.A. Investors of Important December 22 Deadline in Securities Class Action - IPHA Newsfile
04:00PM	Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Las Vegas Sands, Innate Pharma, JPMorgan, and First American Financial and Encourages Investors to Contact the Firm GlobeNewswire
12:00PM	Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA) GlobeNewswire
11:45AM	IMPORTANT DECEMBER DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Innate Pharma S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
11:15AM	DEADLINE ALERT for LVS, IPHA, JPM, and FAF: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:00AM	LVS, IPHA & JPM Class Actions: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Encourages Shareholders to Contact the Firm GlobeNewswire
09:06AM	LOOMING DEC. 22 DEADLINE Pawar Law Group Announces a Securities Class Action Lawsuit Against Innate Pharma S.A. IPHA GlobeNewswire
Dec-08-20 12:20PM	FINAL DEADLINE IMMINENT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Innate Pharma S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sezary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; and IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway. Its products in preclinical trials include IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH61, NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, an anti-MICA/B antibody drug conjugate; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; Anti-Siglec-9, an antibody program; IPH25, a checkpoint inhibitor; and IPH62, an NKp46-NKCE platform. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience